Nectar Lifescience Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 27, 2025, 12:56 pm

Quick Insight

Nectar Lifescience Ltd's current market price of ₹15.1 reflects a P/BV ratio of 0.63x, indicating the stock may be undervalued in relation to its book value. The company's negative operating profit margin of -22% and net profit of -₹114Cr raise concerns about its profitability and cost management. With a ROE of 11.2% and ROCE of 5.36%, Nectar Lifescience's returns are below industry averages, suggesting a need for operational improvements to enhance shareholder value. Furthermore, its high level of borrowings at ₹582Cr and CCC of 143 days indicate potential liquidity challenges. Investors should closely monitor the company's financial performance and management strategies to assess its turnaround potential and long-term viability in the pharmaceutical sector.

Competitors of Nectar Lifescience Ltd

All Competitor Stocks of Nectar Lifescience Ltd

Quarterly Result

Last Updated: August 20, 2025, 6:20 am

Below is a detailed analysis of the quarterly data for Nectar Lifescience Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 281.00 Cr.. The value appears to be declining and may need further review. It has decreased from 431.00 Cr. (Mar 2025) to 281.00 Cr., marking a decrease of 150.00 Cr..
• For Expenses, as of Jun 2025, the value is 343.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 585.00 Cr. (Mar 2025) to 343.00 Cr., marking a decrease of 242.00 Cr..
• For Operating Profit, as of Jun 2025, the value is -62.00 Cr.. The value appears strong and on an upward trend. It has increased from -154.00 Cr. (Mar 2025) to -62.00 Cr., marking an increase of 92.00 Cr..
• For OPM %, as of Jun 2025, the value is -22.00%. The value appears strong and on an upward trend. It has increased from -36.00% (Mar 2025) to -22.00%, marking an increase of 14.00%.
• For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
• For Interest, as of Jun 2025, the value is 19.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 18.00 Cr. (Mar 2025) to 19.00 Cr., marking an increase of 1.00 Cr..
• For Depreciation, as of Jun 2025, the value is 17.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 16.00 Cr. (Mar 2025) to 17.00 Cr., marking an increase of 1.00 Cr..
• For Profit before tax, as of Jun 2025, the value is -97.00 Cr.. The value appears strong and on an upward trend. It has increased from -188.00 Cr. (Mar 2025) to -97.00 Cr., marking an increase of 91.00 Cr..
• For Tax %, as of Jun 2025, the value is -35.00%. The value appears to be improving (decreasing) as expected. It has decreased from -31.00% (Mar 2025) to -35.00%, marking a decrease of 4.00%.
• For Net Profit, as of Jun 2025, the value is -63.00 Cr.. The value appears strong and on an upward trend. It has increased from -130.00 Cr. (Mar 2025) to -63.00 Cr., marking an increase of 67.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is -2.82. The value appears strong and on an upward trend. It has increased from -5.80 (Mar 2025) to -2.82, marking an increase of 2.98.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: July 22, 2025, 3:19 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 2:41 pm

Below is a detailed analysis of the balance sheet data for Nectar Lifescience Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 22.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 22.00 Cr..
• For Reserves, as of Mar 2025, the value is 934.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,047.00 Cr. (Mar 2024) to 934.00 Cr., marking a decrease of 113.00 Cr..
• For Borrowings, as of Mar 2025, the value is 582.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 636.00 Cr. (Mar 2024) to 582.00 Cr., marking a decrease of 54.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 509.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 486.00 Cr. (Mar 2024) to 509.00 Cr., marking an increase of 23.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 2,047.00 Cr.. The value appears to be improving (decreasing). It has decreased from 2,191.00 Cr. (Mar 2024) to 2,047.00 Cr., marking a decrease of 144.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 633.00 Cr.. The value appears to be declining and may need further review. It has decreased from 643.00 Cr. (Mar 2024) to 633.00 Cr., marking a decrease of 10.00 Cr..
• For CWIP, as of Mar 2025, the value is 57.00 Cr.. The value appears to be declining and may need further review. It has decreased from 66.00 Cr. (Mar 2024) to 57.00 Cr., marking a decrease of 9.00 Cr..
• For Investments, as of Mar 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 1.00 Cr..
• For Other Assets, as of Mar 2025, the value is 1,357.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,482.00 Cr. (Mar 2024) to 1,357.00 Cr., marking a decrease of 125.00 Cr..
• For Total Assets, as of Mar 2025, the value is 2,047.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,191.00 Cr. (Mar 2024) to 2,047.00 Cr., marking a decrease of 144.00 Cr..

Notably, the Reserves (934.00 Cr.) exceed the Borrowings (582.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Key Financial Ratios

After reviewing the key financial ratios for Nectar Lifescience Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 24, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 24, the value is 0.22. This value is below the healthy minimum of 5. It has increased from -1.08 (Mar 23) to 0.22, marking an increase of 1.30.
• For Diluted EPS (Rs.), as of Mar 24, the value is 0.22. This value is below the healthy minimum of 5. It has increased from -1.08 (Mar 23) to 0.22, marking an increase of 1.30.
• For Cash EPS (Rs.), as of Mar 24, the value is 2.93. This value is below the healthy minimum of 3. It has increased from 1.56 (Mar 23) to 2.93, marking an increase of 1.37.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 47.68. It has increased from 47.47 (Mar 23) to 47.68, marking an increase of 0.21.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 47.68. It has increased from 47.47 (Mar 23) to 47.68, marking an increase of 0.21.
• For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 75.10. It has increased from 67.94 (Mar 23) to 75.10, marking an increase of 7.16.
• For PBDIT / Share (Rs.), as of Mar 24, the value is 7.41. This value is within the healthy range. It has increased from 4.29 (Mar 23) to 7.41, marking an increase of 3.12.
• For PBIT / Share (Rs.), as of Mar 24, the value is 4.70. This value is within the healthy range. It has increased from 1.65 (Mar 23) to 4.70, marking an increase of 3.05.
• For PBT / Share (Rs.), as of Mar 24, the value is 0.81. This value is within the healthy range. It has increased from -1.89 (Mar 23) to 0.81, marking an increase of 2.70.
• For Net Profit / Share (Rs.), as of Mar 24, the value is 0.22. This value is below the healthy minimum of 2. It has increased from -1.08 (Mar 23) to 0.22, marking an increase of 1.30.
• For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 0.22. This value is below the healthy minimum of 2. It has increased from -1.08 (Mar 23) to 0.22, marking an increase of 1.30.
• For PBDIT Margin (%), as of Mar 24, the value is 9.86. This value is below the healthy minimum of 10. It has increased from 6.31 (Mar 23) to 9.86, marking an increase of 3.55.
• For PBIT Margin (%), as of Mar 24, the value is 6.25. This value is below the healthy minimum of 10. It has increased from 2.43 (Mar 23) to 6.25, marking an increase of 3.82.
• For PBT Margin (%), as of Mar 24, the value is 1.08. This value is below the healthy minimum of 10. It has increased from -2.78 (Mar 23) to 1.08, marking an increase of 3.86.
• For Net Profit Margin (%), as of Mar 24, the value is 0.29. This value is below the healthy minimum of 5. It has increased from -1.58 (Mar 23) to 0.29, marking an increase of 1.87.
• For NP After MI And SOA Margin (%), as of Mar 24, the value is 0.29. This value is below the healthy minimum of 8. It has increased from -1.58 (Mar 23) to 0.29, marking an increase of 1.87.
• For Return on Networth / Equity (%), as of Mar 24, the value is 0.46. This value is below the healthy minimum of 15. It has increased from -2.27 (Mar 23) to 0.46, marking an increase of 2.73.
• For Return on Capital Employeed (%), as of Mar 24, the value is 8.65. This value is below the healthy minimum of 10. It has increased from 2.85 (Mar 23) to 8.65, marking an increase of 5.80.
• For Return On Assets (%), as of Mar 24, the value is 0.22. This value is below the healthy minimum of 5. It has increased from -1.10 (Mar 23) to 0.22, marking an increase of 1.32.
• For Long Term Debt / Equity (X), as of Mar 24, the value is 0.13. This value is below the healthy minimum of 0.2. It has decreased from 0.21 (Mar 23) to 0.13, marking a decrease of 0.08.
• For Total Debt / Equity (X), as of Mar 24, the value is 0.59. This value is within the healthy range. It has decreased from 0.70 (Mar 23) to 0.59, marking a decrease of 0.11.
• For Asset Turnover Ratio (%), as of Mar 24, the value is 0.76. It has increased from 0.66 (Mar 23) to 0.76, marking an increase of 0.10.
• For Current Ratio (X), as of Mar 24, the value is 1.50. This value is within the healthy range. It has decreased from 1.59 (Mar 23) to 1.50, marking a decrease of 0.09.
• For Quick Ratio (X), as of Mar 24, the value is 0.59. This value is below the healthy minimum of 1. It has decreased from 0.62 (Mar 23) to 0.59, marking a decrease of 0.03.
• For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.42. This value is below the healthy minimum of 4. It has increased from 1.39 (Mar 23) to 1.42, marking an increase of 0.03.
• For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 23) which recorded 0.00.
• For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 23) which recorded 0.00.
• For Earning Retention Ratio (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 23) which recorded 0.00.
• For Cash Earning Retention Ratio (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 23) which recorded 0.00.
• For Interest Coverage Ratio (X), as of Mar 24, the value is 1.91. This value is below the healthy minimum of 3. It has increased from 1.21 (Mar 23) to 1.91, marking an increase of 0.70.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 1.06. This value is below the healthy minimum of 3. It has increased from 0.69 (Mar 23) to 1.06, marking an increase of 0.37.
• For Enterprise Value (Cr.), as of Mar 24, the value is 1,290.98. It has increased from 1,091.93 (Mar 23) to 1,290.98, marking an increase of 199.05.
• For EV / Net Operating Revenue (X), as of Mar 24, the value is 0.76. This value is below the healthy minimum of 1. It has increased from 0.71 (Mar 23) to 0.76, marking an increase of 0.05.
• For EV / EBITDA (X), as of Mar 24, the value is 7.77. This value is within the healthy range. It has decreased from 11.35 (Mar 23) to 7.77, marking a decrease of 3.58.
• For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 0.40. This value is below the healthy minimum of 1. It has increased from 0.23 (Mar 23) to 0.40, marking an increase of 0.17.
• For Retention Ratios (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 23) which recorded 0.00.
• For Price / BV (X), as of Mar 24, the value is 0.63. This value is below the healthy minimum of 1. It has increased from 0.33 (Mar 23) to 0.63, marking an increase of 0.30.
• For Price / Net Operating Revenue (X), as of Mar 24, the value is 0.40. This value is below the healthy minimum of 1. It has increased from 0.23 (Mar 23) to 0.40, marking an increase of 0.17.
• For EarningsYield, as of Mar 24, the value is 0.01. This value is below the healthy minimum of 5. It has increased from -0.06 (Mar 23) to 0.01, marking an increase of 0.07.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness